The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A quite ridiculous post, if you don't mind me saying, bald eagle. Extremely surprised that some don't think this warrants an update:
""This work is progressing, and we expect Thornton & Ross to respond by the end of February 2020 within the timelines agreed with the MHRA."
But I suppose FUM shareholders only want to hear what they want to hear.
To issue an RNS costs money, I don't think it is an inconsequential amount. Also investors would get a bit peeved to see lots of pointless RNS's (& FUM wasting resources on issuing them). The AIM authorities might also dislike a company inapproriately using the RNS system .
13p one and half mill after hours a sell , really , fgs if anything over ask paid
Good morning, bald eagle, I hope you are well. I agree that the TPR update is not RNS-able, I get that. But the latest update by FUM wasn't RNS-able either. It's just that one would have thought FUM would "WANT" to tell the Market if Thornton had replied as per FUM's own website:
"This work is progressing, and we expect Thornton & Ross to respond by the end of February 2020 within the timelines agreed with the MHRA."
The Market in general is very fragile at the moment, so IF things are going as planned then it surprises me that FUM aren't at least giving that update, hence my own view that TPR is going belly up.
If I was to back the Market or Lombard, the Italian, I would back the Market. Lombard have a poor track record of getting things wrong, plus they are an "indirect" holding anyway so could just be a client, etc. They've also played this before, "topping up" (hey that's my name!) then offloading. Eg, who dumped the 1.5 million shares after hours yesterday? Lombard? Pah!
Your right our major shareholder are over 21% now , very large top ups , they are not buying on a whim , they know
I agree with The.Italian, there was no requirement nor expectation that FUM would update the market on Thornton & Ross supplying the regulator with additional TPR test information. The need for an RNS would occur when the regulator gives their ruling or if there is meaningful news that impacts FUM, supplying the regulator with additional data doesn't merit an RNS IMO.
doesn't seem as though Lombard Odier agree with that prognosis though.
Still not celebrating your 1p short , lol
And what's more, the Italian, if there is yet another fund raise again at a sub 10p placing, that would mean well over 100 million recent/new shares placed at 7p/8p which means a permanent re-basing of the SP and ultimate expectations. Far too heavily diluted IMO to make this a worthwhile punt, especially if TPR is returned leaving just the (as yet) unpatented placebo.
My guess is an after hours RNS giving bad news, late Fridays are notorious for bad news RNSs!
@Lord - FUM to reassure its shareholders ?? Companies don't work to reassurre the shareholders. They work what they are supposed to and update the market when the information is deemed to be an RNS.
yes happy to agree to disagree and to wait for time to reveal all.
Very relieved to hear that you're OK, the Italian.
I think we'll have to agree to disagree concerning the TPR update. Personally I think it's very important FUM reassures its shareholders that Thornton have responded in the time frame set by the MHRA. Very very important.
lord top up whilst i completely accept that the market should be updated as to the position re TPR in due course, i am just making the point which i think is perfectly valid, that it is premature to draw adverse conclusions from the absence as yet of any update.We need to allow time for feedback from MHRA which could be some time.thank you for your good wishes but I'm not actually Italian and don't live in Italy. its just a board soubriquet.
Lol,
It is patented , more lies
I would have thought it's in FUM's best interests, the Italian (I hope you're not affected by the coronavirus by the way), for them to inform investors that everything is OK as they state on their website:
"This work is progressing, and we expect Thornton & Ross to respond by the end of February 2020 within the timelines agreed with the MHRA."
A return of TPR is very serious. It removes potential future income thereby meaning a further fund raise is almost certain. It also brings into question what the problems are, and given TPR contains dermasys, if there are serious "practical" issues which may also scupper the remaining product - the (as yet) unpatented placebo.
Deramper 70 plus messages and shorts to make 1p , its so funny
He could have brought for 8p and sold 15p , but as he is a super trader chose the 1p route , you couldn’t make it up or maybe you could lol
More lies ,
Thought you would be spending your super short of 1p you spent two weeks raving you were doing
Super trader
Lmao
i don't think we should necessarily expect any form of update re TPR100 at this point.assuming the addition work has been carried out and submitted FUM may simply wait until they have the MHRA's response before updating the market.in that way they would have something substantive to say one way or the other.just my opinion.
Can't say I'm surprised with this inept uncaring management. So will there be an after hours RNS or one on Monday saying Thornton have failed to meet the timeframe set by the MHRA?
Cast your mind back to the height of FUM's potential 3 years ago when they updated the Market:
MED - "Breakthrough results in clinical study showing efficacy, safety and speed of onset, with the potential to be the world's fastest-acting treatment for ED. Advisors appointed to assist in securing out-licensing partners"
CSD - "Two new licensing agreements signed for CSD500 with a further agreement announced in March 2017, bringing network of international partners to a total of eight"
TPR - "First out-licensing agreement signed in January 2017 for TPR100 in the UK. Ongoing out-licensing discussions with prospective partners for TIB200 and TPR100 (outside of the UK)"
A return of TPR would see FUM left with an (as yet) unpatented placebo. What a sad demise.